<aside> 🧫 Orakl’s aims to seamlessly integrate AI tools in our culture, screening and analysis protocols. In the short-term, we believe our edge will come from turbo-charging the existing state-of-the-art AI models with our unique high-quality data.

</aside>

AI-driven drug discovery has an extremely promising future

The industry’s upcoming bottleneck: original data

The new AI moat: generating your own high-quality data

The hype AI biotechs have been disappointing and need more relevant models